本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HANGZHOU, China, March 29, 2025 /PRNewswire/ -- On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its 2024 annual results. In 2024, the Company reported revenue of USD 109.4 million, a year-on-year increase of 48.3%, and achieved a net profit exceeding USD 14 million, marking its first full-year profitability. Amid a dynamic market environment, Zylox-Tonbridge benefited from the economies of scale driven by sustained revenue growth, entering a new phase of sustainable profitability. This fully demonstrates the Company's robust capabilities in developing comprehensive product solutions, delivering high-quality products, and operating efficiently. Looking ahead, Zylox-Tonbridge remains committed to its mission of "Innovation for Quality Life", focusing on advancements in medical technology to improve high-quality healthcare and drive the Company's long term growth. Strong Performance in Centralized Procurement and Continued Overseas Expansion In 2024, the Company actively seized opportunities in centralized procurement, securing successful multiple bids by leveraging its robust and high-quality product portfolio. These achievements are expected to accelerate product penetration in hospitals and enhance market competitiveness, laying a solid foundation for sustained growth. In the "3+N" provincial alliance centralized procurement led by Hebei, our SilverSnake Intracranial Support Catheter fully demonstrated its advantages in the A group for its respective category, winning the bid with the highest ranking. During the national-level venous stent procurement, the ZYLOX Penguin Peripheral Venous Stent System became the only domestic bidder to win the first rule of iliac vein indication. In the vascular intervention product procurement led by Hebei Province, our products, including the Kylin Flow Diverter, White Horse Intracranial PTA Balloon Catheter (Rx) and three peripheral balloon products, won bids, each securing a leading position in their respective categories. As centralized procurement policies deepen, the Company has established an extensive distribution network covering over 3,000 hospitals. In 2024, Zylox-Tonbridge allocated dedicated resources across key functions, including R&D, regulatory affairs, and manufacturing, further expanding its overseas footprint. Currently, 20 of the Company's products are commercialized in 24 countries and regions, including Germany, Italy, Argentina, Brazil, and the UAE, spanning Europe, South America, and the Middle East. The Company is conducting post-market clinical trials for the Zenflex™ Peripheral Stent System and ZENFLEX™ Pro Peripheral Drug-Eluting Stent System in overseas markets while actively participating in international academic conferences such as WLNC 2024, LINC 2024, and CIRSE 2024 to enhance brand influence abroad. The Company's overseas revenue reached USD 3.2 million in 2024, with a four-year compound annual growth rate of 87%. Driven by Innovation: Pioneering Cutting-Edge Medical Technologies In 2024, Zylox-Tonbridge launched multiple innovative products, offering patients more comprehensive solutions. The Company is also actively exploring "AI + Healthcare" technologies to empower product innovation and service upgrades. Among its breakthroughs, the launch of ZYLOX Penguin Peripheral Venous Stent System, a product of medical-engineering collaboration, became another milestone in the Company's efforts to address peripheral venous diseases. The Kylin Flow Diverter, independently developed by Zylox-Tonbridge, is China's first fully visible distal closed flow diverter stent. Meanwhile, ZYLOX Unicorn Suture-mediated Closure System, the first domestically manufactured vascular suture product, has broken the market monopoly of imported brands in puncture site closure solutions. The Company's collaboratively developed ZYLOX Pantheris™ Peripheral OCT-Guided Atherectomy Catheter and ZYLOX Tigereye ST™ OCT-Guided Peripheral Vascular Chronic Total Occlusion-crossing Catheter obtained approval from the NMPA to enter the special review procedure for innovative medical devices (innovation channel), which are expected to launch in 2025. Additionally, Zylox-Tonbridge is focusing on next-generation real-time imaging AI diagnostics and analysis technologies to improve precision in vascular interventions and develop personalized treatment solutions. As of the announcement date, the Company has established a pipeline of 66 products. Among these, 47 have received NMPA approval, 8 have obtained EU CE marks, and several others have been approved for sale in countries such as Germany and the UK. Operational Excellence: Entering the Sustainable Profitability Stage With growing revenue, Zylox-Tonbridge's operational efficiency continues to rise. In 2024, the Company reduced its R&D, sales, and administrative expense ratios by 20, 9, and 10 percentage points, respectively, compared to 2023, propelling it into a new phrase of sustainable profitability. At its Hangzhou and Zhuhai manufacturing bases, the Company has invested in automated and digital production lines, optimized lean processes, and strengthened supply chain management to increase the localization rate of core materials, ensuring both product quality and production efficiency. Since fully launching commercialization in late 2020, over 800,000 of the Company's products have been used clinically, earning recognition and trust from medical professionals. Moving forward, Zylox-Tonbridge will uphold its commitment to "Innovation for Quality Life," increasing investments in medical technology to provide global patients with high-quality, affordable medical devices and solutions. The Company aims to ensure that everyone can benefit from advanced medical technologies, contributing to the progress of the healthcare industry.
SHENZHEN, China, March 29, 2025 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the "Group") announced the audited consolidated results for the year ended 31 December 2024 (the "Reporting Period"). Revenue increased steadily: The revenue of the Group was approximately RMB1,303.7 million for the year ended 31 December 2024, representing a year-on-year growth of approximately 2.9%. International business made a significant growth: The overseas sales of the Group was approximately RMB346.6 million for the year ended 31 December 2024, representing a year-on-year growth of approximately 26.0%. The two largest overseas markets, namely Asia (excluding China's mainland) and Europe, achieved a sustained rapid growth during the Reporting Period, increasing by approximately 33.6% and 18.6% as compared with the same period of 2023, respectively. Profitability：During the Reporting Period, gross profit was approximately RMB981.4 million, while the gross profit margin was approximately 75.3%. Net profit for the year ended 31 December 2024 was approximately RMB168.5 million, and net profit attributable to owners of the Company for the year ended 31 December 2024, was approximately RMB222.4 million. International Business Achieved Significant Growth, Domestic Market Solidified Foundation for Development The Company steadfastly pursued its mission to meet unmet clinical treatment needs worldwide through a strategic lens focused on innovation and global outreach. During the Reporting Period, the Group has showcased its commitment by rolling out a rich product portfolio of cutting-edge technology and premium academic services, alongside the synergistic amalgamation of its expertise in branding, patents, distribution networks, clinical trials, market registration, and management of global operations. With the effective implementation of the internationalization development strategies, the Group's international business has maintained sustained rapid growth. The revenue generated from overseas market of the Group was approximately RMB346.6 million, representing a significant year-on-year growth of approximately 26.0%, accounted for about 26.6% of the total revenue of the Group. Meanwhile, Asia (excluding China's mainland) and Europe were the two largest overseas market of the Group, continued to maintain a strong growth rate during the Reporting Period, increasing by approximately 33.6% and 18.6% as compared with the same period of 2023, respectively. The sales generated from the Asia market and European market accounted for approximately 11.7% and 10.1% of the total revenue of the Group, respectively. China's mainland remained the foundation and the largest market of the Group. During the Reporting Period, the domestic sales of the Group was approximately RMB957.1 million, which accounted for approximately 73.4% of the total revenue of the Group. The Group's key products, including congenital heart disease (CHD) occluders, left atrial appendage (LAA) occluders, aortic stent grafts and vena cava filters, continued to develop in depth in the China's mainland market during the reporting period, with a wide coverage and a solid market foundation, and continuously maintained its leading position in China market. Core Business Demonstrated Development Resilience Structure Heart Diseases (SHD) Business The products offered by the Group in the SHD business mainly include CHD occluders and LAA occluders. The turnover contributed by the SHD business for the year ended 31 December 2024 was approximately RMB527.6 million, representing a year-on-year growth of approximately 6.4%. The LAA occluder of the Group firmly ranks first in terms of market share among domestic peers in the global market. The revenue generated from the sales of LAA occluders increased by approximately 12.4% as compared with the corresponding period of 2023. Meanwhile, the Group is currently selling three generations of CHD occluders in the global market, aiming to meet various market needs through a differentiated product strategy. During the Reporting Period, the revenue generated from the sales of CHD occluders increased by approximately 2.9% as compared with the same period of 2023. The Group has a diversified product portfolio in the treatment of SHD. Continuous technological innovation and product upgrading will further refine and enrich the product portfolio and sales layout of the Group's SHD business in the global market. Peripheral Vascular Diseases (PVD) Business Products offered by the Group in the PVD business mainly included vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts and iliac artery bifurcation stent grafts. During the Reporting Period, the turnover contributed by the PVD business was approximately RMB751.1 million, representing a year-on-year growth of approximately 6.2%. Among these products, the market shares of vena cava filters and stent grafts occupy a leading position in the domestic market. The revenue generated from the sales of stent grafts and vena cava filters increased by approximately 8.3% and decreased by approximately 3.4% as compared with the same period of 2023, respectively. The Group is striving to provide global patients with technology-leading systemic and comprehensive interventional medical devices solutions to treat PVD. Currently, the Group has taken the lead in building an overall solution for endovascular interventional treatment of the aorta in the global industry. This could bring the Group's PVD business with a strong and long-term competitive edge in the global market. Cardiac Pacing and Electrophysiology (CPE) Business The Group is the first domestic manufacturer in China with a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions. During the Reporting Period, the turnover contributed by the CPE business was approximately RMB25.0 million. Innovation at the Core to Drive the Sustainable Growth Independently developed innovative medical device products could maintain the long-term competitive strengths of the Group to support its solid and sustained development. With a robust lineup of pipeline products, the Group is at the forefront of innovation, boasting products with substantial growth potential and broad market appeal. During the Reporting Period, research and development expenses of the Group were approximately RMB302.9 million (excluding capitalized expenditure) to continuously strengthen its innovation capabilities and accelerate the development and commercialization of its novel products. Smooth progress of product commercialization: Futhrough™Endovascular Needle System, Thrombectomy Aspiration Pump, Balloon Guided Catheter, Distal Access Catheter Kits, Intracranial Aspiration Catheter and HeartTone™ Implantable Cardiac Pacemaker compatible with magnetic resonance imaging ("MRI") obtained the National Medical Products Administration ("NMPA") certification; HeartR™ PDA Occluder, Cera™ PDA Occluder, CeraFlex™ PDA Closure System and Fustar™ Steerable Introducer obtained the CE MDR (Medical Device Regulation) certification. Such products have previously obtained the CE MDD (Medical Device Directive) certification; Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System) 【1】, Aortic Arch Stent Graft System (consists of the Ankura™ Plus Aortic Arch Stent Graft System and CSkirt™ Aortic Arch Branch Stent Graft System), Thoracoabdominal Artery Stent Graft System (consists of the G-Branch™ Thoracoabdominal Aortic Stent Graft System, SilverFlow™ PV Peripheral Vascular Stent Graft System and Aortic Extension Stent Graft System), Peripheral Balloon Dilatation Catheter (Large diameter) 【2】, Iliac Bifurcation Device (consists of the G-iliac™ Pro Iliac Bifurcation Stent Graft System and SilverFlow™ Pro Internal Iliac Stent Graft System), Closure Delivery System, SteerEase™-m Introducer, Yoscop™ Multi-loop Snare System and Microcatheter are pending registration approval in China; Note 【1】【2】：Market registration of these two products was approved by NMPA in 2025. Aortic Stent Graft System (consists of the Ankura™ Pro Aortic Stent Graft System and Longuette™ Aortic Branch Stent Graft System), Fitaya™ Vena Cava Filter System, Futhrough™ Stent Graft Balloon Catheter, Yuranos™ Abdominal Aortic Stent Graft System, and G-iliac™ Iliac Bifurcation Device are pending registration approval of CE certification; Cera™ PFO Occluder, CS™ Concave Supra-arch Branched Stent-Graft System and X-Clip™ Mitral Valve Clip System are currently at the stage of the pre-registration clinical enrollment in China; IBS Titan™ Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold System is currently at the stage of clinical enrollment in China and in Europe and its CE registration application has been submitted; and IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has successfully completed the oneyear follow-up and two-year imaging follow-up of the phase II clinical study, and also successfully completed the one-year follow-up of the phase III clinical study, further confirming its safety and efficacy. Additionally, its CE registration application has been submitted. Intellectual Property Rights: Intellectual property is an internal driving force to improve the Group's core competitiveness in the medical device market. As at 31 December 2024, the Group had filed a total of 2,426 valid patent applications, of which 1,089 patents were registered and valid. The Chairman and CEO of LifeTech, Mr. XIE Yuehui Said:In 2024, the Group continued to forge ahead in a complex and volatile market environment. We faced challenges head-on and made joint efforts in research and development, network expansion, production and quality control, and internal control management. We continuously consolidated our leading position in the domestic market and achieved sustained and rapid growth in the international market, demonstrating strong resilience in business development and growth potential. The global medical device industry will embrace tremendous development opportunities driven by both technological innovation and demand upgrading. We will continue to be empowered by innovation, earn a reputation through quality, solidify the foundation for development, and keep delving deeper and making breakthroughs in the global market. We will bring sustainable differential competitive advantages through technological innovation so as to occupy a higher share of the global market and enable more patients to benefit from our innovative products and advanced therapies. Meanwhile, we will also strategically explore new growth opportunities around the globe, integrate and efficiently utilize internal and external advantageous resources, and constantly enhance the overall value of the Group and its global industry influence, so as to create greater value for shareholders and all relevant parties. About LifeTech Scientific Corporation: Established in Shenzhen, China in 1999, LifeTech Scientific Corporation (Stock Code: 1302.HK) is dedicated to the research and development, manufacturing, and marketing of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases. The Company offers innovative treatment solutions for structural heart diseases, peripheral vascular diseases, bradycardia, and neurological diseases. The Company also holds the world's first innovative iron-based bioabsorbable material technology platform. Adhering to the core strategy of innovation and internationalization, the Company maintains a leading market share of its main products in the home country. To date, it has established 7 subsidiaries outside the China mainland. Its business network spans nearly 120 countries and regions worldwide, underscoring its extensive global footprint.
Co-located with APHM Conference & Exhibition, the Event Brings Together 200+ Exhibitors and 5,000+ Industry Professionals KUALA LUMPUR, Malaysia, March 28, 2025 /PRNewswire/ -- The Health Industry Series (tHIS ASEAN) 2025, one of the biggest medical and healthcare exhibitions in the ASEAN region, will take place from June 9 to 11 at the Kuala Lumpur Convention Centre in Malaysia. Spanning over 5,000 square meters, the event will feature over 200 leading companies, showcasing the latest innovations in medical technology to more than 5,000 healthcare professionals from Southeast Asia. tHIS ASEAN 2025, organized by Reed Sinopharm Exhibitions , will coincide with the Association of Private Hospitals of Malaysia (APHM)'s annual conference and exhibition, enabling resource sharing and attracting a diverse audience, including hospital procurement managers and distributors. Established in 1972, APHM covers over 77% of Malaysia's private healthcare sector. This collaboration marks a significant milestone in the industry's development in Southeast Asia and is expected to attract government officials, medical association representatives, and other key stakeholders from across the region. As an extension of CMEF, PHARMCHINA, CRS, CHCC, and ICMD, it is providing a comprehensive platform for medical innovation. Nowadays, more innovative drugs, TCM, OTC medicines, health supplements, medical devices, and personal care products are entering the global market."Chinese medical devices are highly sought after in Malaysia for their excellent performance, quality, and cost-effectiveness," said Datuk Dr. Kuljit Singh, President of APHM. "This collaboration marks the first large-scale collective appearance of Chinese medical device companies in Malaysia, offering local healthcare institutions a better understanding of these products and providing a platform for Chinese companies to expand their global markets." Rising Demand for Innovative Medical Devices, Pharmaceuticals, and Treatments in ASEAN Remote Surgery: The next-generation multi-port endoscopic surgical robot can perform complex level-4 procedures, representing a major advancement in surgical precision and efficiency. AI-Powered Assistants: uAI Avatar, an intelligent assistant, interacts with doctors, assists in equipment operation, and retrieves critical information—enhancing efficiency and accuracy while shaping the future of healthcare. Rehabilitation Advancement: The lower limb exoskeleton robot, designed with bionics and ergonomics, is an external support system that supports human weight and provides powered assistance to enhance limb and motor function recovery. Hospital Infrastructure: The latest nurse call system features an efficient response mechanism and a user-friendly design for both medical staff and patients. It ensures timely medical support for patients and significantly enhances the efficiency of healthcare providers in delivering care. A Sneak Peek at the Event Highlights Professional Forums: Five insightful conferences on medical innovation trends, covering AI-powered technologies, future pharmaceutical innovations, the hospital of the future, ASEAN rehabilitation and elderly care, and healthcare regulation in ASEAN. 1-on-1 Business Matching: Tailored meetings connecting Chinese exhibitors with ASEAN buyers for efficient resource alignment. Traditional Chinese Medicine (TCM) Experience: Live demonstrations and hands-on activities showcasing TCM techniques and devices. For pre-registration, please click: https://reg.reed-sinopharm.com/pc/#/login?id=f86b6683b7c74190a84bfa4d7aa8eab1&channelUuid=89b1482312f44747be891a0cdb0190ce
BOSTON, March 28, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, has been named a winner of the 2025 BSMA Supply Chain Management Innovation Award for its Multienterprise Information Network Tower (MINT) solution. The BSMA Supply Chain Management Innovation Award recognizes outstanding contributions to supply chain excellence in the biotech and life sciences industry. Winners are selected by a panel of industry leaders and are honored for their innovative strategies, measurable impact, and advancement of supply chain performance. For biopharmaceutical companies ready to expand on their serialization and track-and-trace orchestration investments, MINT—delivered through OPUS, the Orchestration Platform for Universal Solutions— is the next step, transforming compliance into a launchpad for end-to-end supply chain digitalization. By eliminating the need for costly point-to-point integrations and instead substituting affordable, scalable, and interoperable links, MINT enables seamless data exchange across thousands of partners through a single integration to the industry's largest digital network of life sciences and healthcare companies. Powered by TraceLink's Integrate Once, Interoperate with Everyone™ model, MINT boosts profitability, efficiency, and agility across the supply chain—helping companies future-proof operations across direct supply management, external manufacturing, logistics, transportation, and commerce. "We're honored that BSMA recognizes the unique journey TraceLink is embarked on to help transform the industry's ability to serve patients globally," said Shabbir Dahod, President and CEO of TraceLink. "For many companies, mandated track-and-trace and compliance requirements were the first step in their digital supply chain journey. MINT builds on that foundation, turning compliance, quality, and patient safety into a strategic advantage. End-to-end digitalization and the ability to orchestrate with trading partners drives agile decision-making, optimizes inventory, improves revenue performance, and provides the digital agility needed to thrive in today's dynamic supply chain environment." A real-world example of the value of MINT—and the driving force behind this award recognition—involved a leading contract packager that sought to eliminate manual processes and reduce the risk of errors across its operations. By embracing TraceLink's digital supply network platform, the company replaced paper-based documentation and disconnected workflows with real-time data exchange and automated processes. This transformation significantly improved visibility, reduced cycle times, and streamlined collaboration with brand owners and contract manufacturing partners. The result: enhanced operational efficiency, faster onboarding of new trading partners, and a more agile, reliable supply chain ready to meet evolving compliance and business demands. "TraceLink's MINT solution was selected for its innovative approach to addressing key challenges in healthcare and life sciences supply chains," said Devendra Mishra, Executive Director and Co-Founder of BSMA. "Their contributions continue to advance the industry—fueling a new era of connectivity and intelligence that ensures product authenticity, protects patient safety, and lays the foundation for a digitally transformed future." Past winners span a wide range of organizations—from emerging biotech firms to global pharmaceutical manufacturers and technology solution providers—demonstrating the breadth of innovation driving the healthcare supply chain forward. Learn more about how this pharmaceutical contract packaging company digitalized its supply chain with MINT. About TraceLinkTraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by linking more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely. About Bio Supply Chain Alliance (BSMA)BSMA is a global industry organization dedicated to advancing supply chain excellence in the life sciences sector. Bringing together pharmaceutical, biotechnology, medical device, and healthcare industry leaders, BSMA fosters collaboration, innovation, and best practices to enhance supply chain resilience, efficiency, and regulatory compliance. BSMA provides a platform for professionals to address critical challenges, leverage emerging technologies, and drive transformative solutions across the global healthcare supply chain. Go to www.biosupplyalliance.com to learn more.
GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Today, Getinge publishes its Annual Report, including Sustainability Report, for 2024. The report summarizes a year characterized by strong growth, increased customer satisfaction, and successful product launches. The global medtech company has reached new sales records, strengthened its acquisitions, and continued to develop innovative solutions that improve healthcare - all while maintaining a strong focus on quality improvements and adapting to increasing market demands. "2024 was a record year for Getinge. We have grown significantly, maintained high customer loyalty, and launched highly demanded products across all business areas," says Mattias Perjos, President & CEO at Getinge. "This has been made possible through our long-term focus on innovation, customer-centricity, and strong collaboration." Throughout the year, Getinge has continued its intensive work on quality improvements. Perjos emphasizes that these experiences have further strengthened the company's commitment to continuous improvements and the importance of adapting quickly to both regulatory requirements and market expectations. "We have a deep commitment to quality and sustainability, which is embedded in everything we do," says Perjos. "We also see a growing demand for our products, which confirms the value of our work and the appreciation our customers have for our solutions." Getinge sees clear global trends, where an aging population, increasing economic pressures, and digitalization present both challenges and opportunities. The company addresses these by working closely with customers and offering solutions that enhance both healthcare workflows and working environments. "Innovation is a central part of our DNA and crucial for remaining relevant to our customers. We continuously develop new therapies and solutions while improving existing products to meet future healthcare needs and ensure long-term sustainability," says Perjos. "Our strategy extends beyond 2030, aiming to double the number of lives saved, enable at least one additional surgery per operating room per day, and ensure that medicines for complex diseases reach patients 25% faster." Sustainability is at the core of Getinge's vision for a future with better and more accessible healthcare. By combining innovative solutions with energy efficiency and sustainable material choices, the company is working to reduce environmental impact while improving global access to healthcare. At the same time, the global market is affected by geopolitical uncertainty, trade barriers, and increased protectionism. "In the end, it is patients and taxpayers who are most at risk of being affected, which is an insight I hope policymakers worldwide take into account," says Perjos, noting that the medtech industry has historically proven to be resilient and that the demand for healthcare continues to grow. 2024 concluded with continued strong demand for Getinge's solutions, and the CEO remains optimistic about the future. "Ongoing investment from hospitals and pharmaceutical companies, combined with our strong market presence, provides great opportunities to continue creating long-term value and making life-saving technology accessible for more people," concludes Perjos. Getinge's Annual Report for 2024, including the Sustainability Report, is available at www.getinge.com. Investor Relations: David Kördel, Head of Investor RelationsPhone: +46 (0)10 335 0077Email: david.kordel@getinge.com Media contact: Caroline Örmgård, Head of Public & Media RelationsPhone: +46 (0)10 335 0041Email: caroline.ormgard@getinge.com This information is information that Getinge AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14.30 CET on March 27, 2025. About GetingeWith a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries. This information was brought to you by Cision http://news.cision.com. https://news.cision.com/getinge/r/getinge-publishes-annual-report-for-2024,c4125484 The following files are available for download: https://mb.cision.com/Main/942/4125484/3350635.pdf Getinge Annual Report 2024 https://mb.cision.com/Public/942/4125484/af4f8a5f09b9f329.pdf Getinge publishes Annual Report for 2024
Highlights of Annual Results for the Year Ended December 31, 2024Revenue reached RMB1,986.7 millionGross profit amounted to RMB687.4 millionNet profit recorded RMB222.0 million, a significant turnaround from a year agoAdjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nearly 50.6%. SHANGHAI, March 27, 2025 /PRNewswire/ -- On March 27, 2025, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue during the Reporting Period achieved RMB1,986.7 million, gross profit amounted to RMB687.4 million and net profit recorded RMB222.0 million, a significant turnaround from a net loss of RMB99.8 million in the corresponding period of last year, mainly benefiting from the elimination of relevant financial adjustments due to the full repayment of convertible bonds, and an increase in adjusted non-IFRS net profit to RMB314.6 million from RMB208.8 million in the corresponding period of last year, representing an increase of nearly 50.6% as compared to last year, which was mainly attributable to an increase in operating profit margin driven by the recovery of CRO business growth and the improving operational efficiency in 2H2024, as well as the recognition of investment income from milestone payments received by the Group during the year. In addition, the Group's subsidiary Viva Biotech Shanghai was successfully restructured into a joint stock limited company on September 27, 2024, as the Group currently holds approximately 72.9% of its total issued share capital. During the Reporting Period, the Group's management and its strategic investors commenced a number of collaborations with full mutual trust, fully utilizing the strategic investors' strengths in global vision, capital markets and strategic resources to empower the Group's continuous enhancement in corporate governance, business operations, investment and financing as well as strategic planning. CRO Revenue Growth Improved Significantly Improving in the Second Half of the Year to Sustain a Recovery Momentum Ahead In 2024, the revenue of the Company's CRO business decreased by approximately 4.0% to RMB810.9 million from RMB844.9 million in the same period of last year, while the corresponding adjusted gross profit decreased by approximately 1.9% to RMB357.1 million from RMB363.8 million in the same period of last year. The decrease in CRO revenue in 2024 as compared to previous years was mainly attributable to the short-term impact of the global biopharmaceutical investment and financing pressure in 2023 on the R&D investment in innovative drugs in 1H2024. However, with the gradual recovery of global biopharmaceutical investment and financing since 2024, the Company's CRO revenue in 2H2024 has realized positive year-on-year and quarter-on-quarter growth compared with the same period last year and the first half of 2024. In addition, the CRO order value has realized positive growth year-on-year, and the monthly new order value is still maintained at a high level, which will drive the Company's CRO revenue to further maintain the rebound trend in 2025. Meanwhile, the Company has also taken a series of effective measures to enhance operational efficiency to maintain the profitability of CRO at a higher level. As of December 31, 2024, the Company's cumulative number of CRO customers increased to 1,568, including the world's top 10 pharmaceutical companies (based on the total revenue of the 2024 annual report), with the revenue share of the top 10 customers accounting for 24.4%. The CRO business has a diversified geographical distribution of customers, with the revenue share from overseas regions accounting for approximately 87.3%. Revenue from customers in Mainland China accounted for approximately 12.7%. As of the end of 2024, the Company has cumulatively delivered more than 82,716 protein structures to the clients, approximately 17,681 of which were newly delivered in 2024. The R&D of the Company has accumulated over 2,098 independent drug targets, 112 of which were newly delivered in 2024. Currently, the Company maintains a leading global position in the industry in the field of protein structure analysis. During the Reporting Period, the utilization of synchrotron radiation source reached 1,867 hours. The Company established long-term cooperation with 13 synchrotron radiation source centers around the world, the Company will ensure uninterrupted data collection throughout the year. In terms of marketing and business development, on one hand, the Company will obtain integrated service orders by fostering synergistic development of biological and chemical segments, on the other hand, the Company will actively continue to enhance the integration of digital marketing and offline business development (BD), while expanding its global BD team. During the Reporting Period, the Group not only strengthened its presence in the European market, but also established a branch in Boston, the United States. This marked a new milestone in the Company's global footprints, allowing us to further expand and deepen the international cooperation network. Moreover, the Company attaches great importance to the important role of artificial intelligence (AI) in drug R&D. Based on the efforts in improving efficiency and success rate, the Company combines dry and wet experiments to expand quantity and scale of new projects continuously. It is worth mentioning that by the end of 2024, the Company had participated in 157 AIDD projects, and the cumulative number of customers purchasing CADD/AIDD reached 51. Revenue from AI-enabled projects exceeded US$10 million, and cooperation with renowned institutions regarding a complete set of AI discovery solutions has been reached in some niche fields. New Commercial CDMO Projects to be Launched Soon and the CMC Business Optimization and Adjustment Largely Completed The Group is committed to building a one-stop service platform from R&D to production of global innovative drugs. Through the 100% equity interests acquisition of Zhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), the Group has been able to complete the deployment of the production side of the business. During the Reporting Period, the Group continued to expand CDMO capacity to prepare for commercial production of new molecules in the future. In addition, the Company completed optimization and adjustment of the CMC business. In 2024, Langhua Pharmaceutical recorded revenue of RMB1,175.7 million and the adjusted gross profit of RMB344.5 million. As of December 31, 2024, Langhua Pharmaceutical had served 897 clients, with 66.8% of revenue accounted for by the top ten customers and 100% retention rate of the top ten customers. Currently, Langhua Pharmaceutical's CDMO business, in addition to the existing commercialized projects that can maintain natural growth, has two important new commercialized projects that are at the process performance qualification (PPQ) stage and are expected to be commercially launched in 2025 and 2026, respectively, which will serve as a new growth driver for the CDMO business in the future. With respect to production capacity, the current total available total capacity has reached 860 cubic meters. In addition, Langhua Pharmaceutical plans to establish a new production capacity of 400 cubic meters between 2024 and 2025 to cater the commercial production of new molecules, and the civil construction work has already been completed. This endeavor will provide sufficient assurance for the Company's revenue growth with the launch of new products and release of reserved capacity in the future. Langhua Pharmaceutical will continue to adhere to the principles of customer first and regulatory compliance in quality management, strengthen cooperation with quality customers, and continuously improve and enhance the guidance and operability of the quality system. During the Reporting Period, Langham Pharmaceutical passed the on-site inspections of WHO and FDA again, which fully demonstrates that the quality system of Langham Pharmaceutical is further well aligned with the international system standards, and can guarantee the provision of quality, safe and reliable CDMO services to the world's leading pharmaceutical enterprises. In 2024, the Group adjusted its CMC business structure by focusing more on synthesis and analytics operations, strengthened BD efforts to overseas customers, and promoted continuous improvement in profitability through cost reduction, efficiency enhancement and customer mix optimization. Since its establishment, CMC has completed and is currently progressing with a total of 255 new drug projects, driven by a CMC R&D team of 105 members, and generated revenue of nearly RMB43.0 million. In addition, the projects channeled by the Group progressed smoothly, and one pipeline has rapidly advanced to Phase III clinical trials, showcasing the success of the Group's integrated strategy. In the future, the Group will further strengthen the BD and channeling efforts for acquiring high-quality CMC projects with a view to promoting revenue growth and profitability improvement of the CMC business on the basis of fully utilizing internal project resources, reducing costs and increasing efficiency. Partial Exits of Incubation Portfolio Companies Continued to Realize Investment Returns, Accretive to the Group's Profits During the Reporting Period, the Company achieved partial investment exits from a number of portfolio companies (Focus-X, Saverna, Dogma, Riparian, DTX and Nerio), realizing corresponding investment returns and generating total proceeds of nearly RMB162.5 million. As of December 31, 2024, the Group had invested in a total of 93 portfolio companies. The portfolio companies are mainly from the United States, Canada, Europe and China. 67.7% of the portfolio companies are from North America and 25.8% are from China. In 2024, 11 of the Company's portfolio companies completed or were close to completing a new round of financing, raising approximately US$292.7 million. The R&D efforts of the portfolio companies were advancing smoothly, with the total number of pipeline projects reaching close to 227, of which 186 pipelines are in the preclinical stage and 41 pipelines in the clinical stage. So far, the Group has successfully realized 15 investment exits or partial exits. Furthermore, the Group may have several potential exits of our portfolio companies, and it also can be foreseen that a peak season of investment exits will arrive in the next three years. As of December 31, 2024, the Company has strategically invested in a series of high-quality assets, including portfolio companies such as Haya, Mediar, Nerio, Full-Life, Absci, Dogma, Arthrosi, Basking, Cybrexa and FuseBio. In the future, as these portfolio companies to develop successfully, secure ongoing financing, and realize exits, the initial investments will gradually enter the harvesting phase, providing sustained cash returns and investment income for the Group. Technology Highlights and R&D Breakthroughs Viva Biotech's artificial intelligence technology, accumulated and developed over many years, is empowering its entire drug discovery platform. The current AI capabilities cover the full workflow of FIC drug discovery and are gradually transforming the logical paradigm of drug discovery through end-to-end integration. By focusing on new targets, novel MOA and new modalities, Viva Biotech has developed distinctive AI capabilities, driving its one-stop innovative drug R&D service platform from "AI-assisted" to "AI-driven". New Target A series of target protein structures not reported in the PDB protein structure database have been delivered to customers. Novel MOA Including allosteric mechanisms, target selectivity and conformational selectivity. Comprehensive drug discovery technologies such as DEL, ASMS, Intact-MS, SPR, NMR, crystal soaking, virtual screening, membrane protein technology, phage display and HTS; as well as various experimental validation techniques including protein crystal structures, Cryo-EM structures, HDX-MS and Bioassay. Additionally, the Company provides medicinal chemistry, computational chemistry, Pharmacology and DMPK services. New Modality Established platforms such as the XDC platform, peptide technology platform, PROTAC/molecular glue platform, and antibody/large molecule R&D technology platform. XDC Platform: Successfully integrated biologics/antibody platforms, peptide platforms, and small molecule drug platforms into the XDC large platform, covering multiple fields and capable of supporting various conjugated molecular models such as ADC, RDC, AOC, APC, DAC, etc. Additionally, the XDC platform has been deeply integrated with AIDD/CADD technologies and DEL technologies. Peptide Technology Platform: At the peptide discovery journey, a new AI-based peptide generation method has been developed, as well as a peptide screening strategy combining DEL/phage display screening data with AI analysis capabilities. Through a multi-dimension peptide research and development approach, the success rate of customer peptide R&D has been comprehensively improved. The company also provides one-stop peptide R&D and partial production services, including synthesis, biological testing, and PK research. PROTAC/ Molecular Glue Platform: PROTAC/molecular glue-related services account for approximately 10.75% of the CRO's total revenue. Over 50 E3 ligases have been researched, and more than 150 PROTAC ternary complexes have been delivered. Macromolecular Drug/Antibody Platform: By combining AIDD/CADD technologies, multiple high-difficulty antibody affinity modification projects and patent breakthroughs have been successfully completed. Furthermore, the antibody R&D platform has been enhanced through the expansion and improvement of bispecific antibody design platforms, high-throughput antibody rapid expression platforms, mRNA immunization, gene gun immunization, and other technologies. AI-enabled SBDD One-Stop Novel Drug R&D Service Platform The Company's AIDD and CADD platforms possess proprietary algorithms and platform-building capabilities, along with experience in developing various drug modalities. Leveraging Viva Biotech's strengths in structure-based drug R&D and supported by the computational power of the Shanghai supercomputing cluster, these platforms comprehensively empower all stages of early drug development. Building on this foundation, Viva Biotech is transitioning from a phase where computational methods primarily supported various drug development stages to a new phase where AI drives drug design, integrates with experimentation, and transforms the drug design paradigm. Staff and Facilities As at December 31, 2024, the Group had a total of 2,063 employees, of whom the number of CRO R&D personnel reached 1,121, and the headcount of Langhua Pharmaceutical was 711. The Company has well-established office and laboratory facilities in line, and is expanding production capacity to meet the fast-growing business needs, including: The Group's headquarters in Zhoupu, Shanghai, with a total area of approximately 40,000 square meters. The incubation center located in Faladi Road, Shanghai has an actual usable area of approximately 7,576 square meters, including 5,552 square meters of laboratory area. The park in Chengdu is approximately 64,564 square meters, of which 12,210 square meters of properties had been put into use as at December 31, 2024, including 10,800 square meters of laboratory area. A park in Suzhou is approximately 7,545 square meters, including nearly 5,305 square meters of laboratory area. A park in Jiaxing is approximately 6,362 square meters, including nearly 5,335 square meters of laboratory area. Shanghai Supercomputing Center has been officially put into operation in 2021. At present, it can support computer-aided drug discovery (CADD) computation, artificial intelligence in drug discovery (AIDD) related computation, and crystal structure and Cryo-EM (Micro-ED) computation. The factory of Langhua Pharmaceutical in Taizhou, Zhejiang is approximately 35,168 square meters, including the Taizhou R&D center with an area of approximately 2,500 square meters. The R&D center of Ningbo Nuobai has an area of approximately 1,300 square meters and the office building of Ningbo Nuobai has an area of approximately 1,500 square meters. Dr. Mao Chen Cheney, Chairman and Chief Executive Officer of Viva Biotech, said, "With unique advantages in structure-based drug R&D (SBDD), the Company will increase the cross-sell between biological and chemical businesses, continue to strengthen the construction of a one-stop drug R&D and manufacturing service platform, deepen the synergy between CRO and CDMO business, improve the capacity building for front-end services and drive business to back-end services to further enhance the business funnel effect. The Company is in an effort to establish an open eco-system for global biopharma innovators. " About Viva Biotech Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs. As of December 31, 2024, Viva Biotech had cumulatively provided drug R&D and manufacturing services to 2,465 biotech and pharmaceutical clients around the world. We have invested and incubated 93 biotech start-ups in total. In the future, the company will continue to strengthen its technological barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.
A12 藝術空間
Pharmaceuticals
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
